GlassScriptPhysician profile
Janine G Tabas
NPI 1073502647
$7,023.37
in general payments reported to CMS, 2019-2025
21 companies · $3,290 in 2025
The $3,290 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $210 · 2021: $1,031 · 2022: $651 · 2023: $760 · 2024: $631 · 2025: $3,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,107 · Travel and Lodging: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,107.27 |
| Travel and Lodging | $1,574.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,692.08 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Bausch & Lomb Americas INC. | $2,257.90 | 2023-2025 | Envista Mx60 Iol, Envista Envy Iol, Envista Aspire Iol |
| Johnson & Johnson Surgical Vision, INC. | $467.40 | 2020-2023 | Tecnis Iol |
| Rxsight INC | $264.31 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Sun Pharmaceutical Industries INC. | $231.31 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $140.36 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $133.46 | 2021 | |
| New World Medical,INC. | $120.48 | 2024 | Streamline, Ahmed Glaucoma Valve, Clearpath |
| Tarsus Pharmaceuticals, INC. | $113.59 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $112.15 | 2025 | Idosetr |
| Carl Zeiss Meditec Cataract Technology INC. | $105.76 | 2021 | |
| Abbvie INC. | $79.20 | 2022-2023 | Vuity, Lumigan, Alphagan P |
| Carl Zeiss Meditec USA, INC. | $58.54 | 2021 | |
| Oyster Point Pharma, INC. | $52.73 | 2022 | |
| Ocular Therapeutix, INC. | $42.60 | 2022-2025 | Dextenza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $42.44 | 2024 | Vevye |
| Omeros Corporation | $32.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.06 | 2019 | |
| Amgen INC. | $21.32 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.69 | 2020 | |
| Horizon Therapeutics Plc | $15.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janine Tabas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.